Adrian M. Di Bisceglie MD

PubMed

• 12 citations
  Randomized Trial of Tenofovir With or Without Peginterferon Alfa Followed by Protocolized Treatment Withdrawal in Adults With Chronic Hepatitis B.
  Norah A Terrault, Anna S Lok, Abdus S Wahed, Marc G Ghany, Robert P Perrillo
  The American Journal of Gastroenterology. 2023-07-01
• 5 citations
  Within-host quantitation of anellovirus genome complexity from clinical samples.
  Peng Peng, Yanjuan Xu, Rajeev Aurora, Adrian M Di Bisceglie, Xiaofeng Fan
  Journal of Virological Methods. 2022-04-01
• Michael Charles Kew - Frontrunner in Hepatology.
  Chris Kassianides, Geoffrey Dusheiko, Adrian Di Bisceglie, Jay H Hoofnagle
  Journal of Hepatology. 2021-12-06

Journal Articles

• TG4040 Immunotherapeutic with Peginterferon/Ribavirin in Chronic HCV Infection: a Randomized Phase II Study  
  Di Bisceglie, Janczweska-Kazek E, Habersetzer F, Mazur W, Stanciu C, Carreno V, Tanasescu C, Flisiak R, Romero-Gomez M, Fich A, Bataille V, Toh M-L, Hennequi M, Zerr P..., Gastroenterology, 1/1/2014
• VX-222, a Non-Nucleoside NSSB Polymerase Inhibitor, in Telaprevir-Based Regimens for Genotype 1 Hepatitis C Virus Infection  
  Di Bisceglie AM, Sulkowski M, Gane E, Jacobson IM, Nelson D, DeSouza C, Alves K, George S, Kieffer T, Zhang EZ, Kauffman R, Asmal M, Koziel MJ, European J Gastroenterol Hepatol, 1/1/2014
• Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection  
  Afdhal N, Reddy R, Nelson DR, Lawitz E, Gordon SC, Schiff E, Nahass R, Ghalib R, Gitlin N, Herring R, Lalezari J, Younes ZH, Pockros PJ, Di Bisceglie AM et al, N Engl J Med, 1/1/2014
• Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis  
  Kowdley KV, Gordon SC, Reddy KR, Rossaro L, Bernstein DE, Lawitz E, Shiffman ML, Schiff E, Ghalib R, Ryan M, Rustgi V, Chojkier M, Herring R, Di Bisceglie AM et al, N Engl J Med, 1/1/2014
• Retreatment of HCV with ABT-450/r-Ombitasvir and dasabuvir with ribavirin  
  Zeuzem S, Jacobson IM, Baykal T, Marinho RT, Poordad F, Bourliere M, Sulkowski MS, Wedermeyer, Tam E, Desmond P, Jensen DM, Di Bisceglie AM et al, N Engl J Med, 1/1/2014
• Prevention of hepatocellular carcinoma due to hepatitis B: are we there yet?  
  Di Bisceglie AM, Clin Gastro Hepatol, 1/1/2014
• Telbivudine Improves Renal Function in Patients with Chronic Hepatitis B  
  Gane EJ, Deray G, Liaw YF, Lim SG, Lai CL, Rasenack J, Wang Y, Papaptheodoridis G, Di Bisceglie A, Buti M, Samuel D, Uddin A, Bosset S, Trylesinski A, Gastroenterology, 1/1/2013
• Potentially Curative Treatment in Patients with Hepatocellular Cancer-Results from the Liver Cancer Research Network  
  Kanwal, Fasiha; Befeler, Alex; Marrero, Jorge; Chari, Ravi; Afdhal, Nid; Morgan, Timothy; Robert, Lewis; Mohanty, Smruti; Schwartz, Jonathan M; Van Thiel, David; Di Bi..., Ali Pharm Ther, 1/1/2012
• Hepatitis C virus induces epithelial-mesenchymal transition in primary human hepatocytes  
  Bose SK, Meyer K, Di Bisceglie AM, Ray RB, Ray R, J Virol, 1/1/2012
• Hepatitis C virus infection modulates expression of interferon stimulatory gene IFITM1 by upregulating miR-130A  
  Bhanja Chowdhury J. Shrivastava S. Steele R. Di Bisceglie AM. Ray R. Ray RB, J Virol, 1/1/2012
• EASL-EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma  
  Di Bisceglie AM (as a clinical practice Guideline Member), J Hepatol, 1/1/2012
• The history of the department of Internal Medicine at Saint Louis University  
  Di Bisceglie AM, Manning C, Holyoke A, Missouri Medicine, 1/1/2012
• Role of the multidisciplinary team in the diagnosis and treatment of hepatocellular carcinoma  
  Gish RG. Lencioni R. Di Bisceglie AM. Raoul JL. Mazzaferro V, Expert review of gastroenterology & hepatology, 1/1/2012
• Transcriptional repression of C4 complement by hepatitis C virus proteins  
  Banerjee A, Mazumdar B, Meyer K, Di Bisceglie AM, Ray RB, Ray R, Journal of Virology, 5/1/2011
• Maintenance Peginterferon Therapy and Other Factors Associated with Hepatocellular Carcinoma in Patients with Advanced Hepatitis C  
  Lok AS, Everhart JE, Wright EC, Di Bisceglie AM, Kim HY, Sterling RK, Everson GT, Lindsay KL, Lee WM, Bonkovsky HL, Dienstag JL, Ghany MG, Morishima C, Morgan TR, HALT..., Gastroenterol, 1/1/2011
• Excess mortality in patients with advanced chronic hepatitis C treated with long-term peginterferon  
  Di Bisceglie AM, Stoddard AM, Dienstag JL, Shiffman ML, Seeff LB, Bonkovsky HL, Morishima C, Wright EC, Snow KK, Lee WM, Fontana RJ, Morgan TR, Ghany MG; for the HALT-..., Hepatology, 1/1/2011
• Telaprevir for Previously Untreated Chronic Hepatitis C Virus Infection  
  Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM et al for the ADVANCE Study Team, N Engl J Med, 1/1/2011
• A prospective study of the rate of progression in compensated histologically advanced chronic hepatitis C  
  Dienstag JL, Ghany MG, Morgan TR, Di Bisceglie AM, Bonkovsky HL, Kim HY, Seeff LB, Szabo G, Wright EC, Sterling RK, Everson GT, Lindsay KL, Lee WM, Lok AS, Morishima C..., Hepatology, 1/1/2011
• Occult and previous hepatitis B virus infection are not associated with hepatocellular carcinoma in United States patients with chronic hepatitis C  
  Lok AS, Everhart JE, Di Bisceglie AM, Kim, H-Y, Hussain M, Morgan TR and the HALT-C trial group, Hepatology, 1/1/2011
• Divergent quasispecies evolution in de novo hepatitis C virus infection associated with bone marrow transplantation  
  Wang W, Lin J, Xu Y, Brunt EM, Fan X, Di Bisceglie AM, Biochem Biophys Res Comm, 1/1/2011
• Novel changes in glycosylation of serum Apo-J in patients with hepatocellular carcinoma  
  Comunale MA, Wang M, Rodemich-Betesh L, Hafner J, Lamontagne A, Klein A, Marrero J, Di Bisceglie AM, Gish R, Block T, Mehta A, Cancer Epidemiology, Biomarkers & Prevention, 1/1/2011
• Prospects for personalizing antiviral therapy for HCV with pharmacogenetics  
  Tavis JE, Donlin MJ, Aurora R, Fan X, and Di Bisceglie AM, Genome Medicine, 1/1/2011
• Procarbazine Hepatotoxicity: Case Report and Review of the Literature  
  Fesler MJ, Becker-Koepke S, Di Bisceglie AM, Petruska PJ, Pharmacotherapy, 1/1/2010
• Des-gamma-carboxy Prothrombin and alpha-fetoprotein as Biomarkers for the Early Detection of Hepatocellular Carcinoma  
  Lok AS, Sterling R, Everhart J, Wright E, Hoefs J, Di Bisceglie AM, Morgan T, Kim H-Y, Lee W, Bonkovsky H, Dienstag J, Gastroenterology, 1/1/2010
• A sustained viral response is associated with reduced liver-related morbidity and mortality in patients with hepatitis C virus  
  Singal AG, Volk ML, Jensen J, Di Bisceglie AM, Schoenfeld PS, Clin Gastro Hepatol, 1/1/2010
• Predicting Clinical and Histological Outcomes Based on Standard Laboratory Tests In Advanced Chronic Hepatitis C  
  Ghany MG, Lok ASF, Everhart JE, Everson GT, Lee WM, Curto TM, Wright EC, Stoddard AM, Sterling RK, Di Bisceglie AM et al for the HALT-C Trial Group, Gastroenterology, 1/1/2010
• Contribution of Genome-Wide HCV Genetic Differences to Outcome of Interferon-Based Therapy in Caucasian American and African American Patients  
  Donlin M, Cannon NA, Aurora R, Li J, Wahed AS, Di Bisceglie AM, Tavis JE, PLoSOne, 1/1/2010
• Changes in quality of life and sexual health are associated with low-dose peginterferon therapy and disease progression in patients with chronic hepatitis C  
  Snow KK, Bonkovsky HL, Fontana RJ, Kim H-Y, Sterling RK, Di Bisceglie AM, Morgan TR, Dienstag JL, Ghany MG, Alimentary Pharmacology & Therapeutics, 1/1/2010
• Factors that determine the development and progression of gastroesophageal varices in patients with chronic hepatitis C  
  Fontana RJ, Sanyal AJ, Ghany MG, Lee WM, Reid AE, Naishadham D, Everson GT, Kahn JA, Di Bisceglie AM, Szabo G, Morgan TR, Everhart JE, Gastroenterology, 1/1/2010
• Enhanced Protocol for Determining the 3' Terminus of Hepatitis C Virus  
  Zhang X, Fan X, Xu Y and Di Bisceglie AM, J Virol Method, 1/1/2010
• Telaprevir for previously treated chronic HCV infection  
  McHutchison JG, Manns MP, Muir AJ, Terrault NA, Jacobson IM, Afdhal NH, heathcote EJ, Zeuzem S, Reesink HW, Garg J, Bsharat M, George S, Kauffman RS, Adda N, Di Bisceg..., N Engl J Med, 1/1/2010
• Safety and Immunogenicity of HCV E1E2 Vaccine Adjuvanted with MF59 Administered to Healthy Adults  
  Frey SE, Di Bisceglie AM, Abrignani S, Ray R, Houghton M, Vaccine, 1/1/2010
• Outcome of Sustained Virological Responders with Histologically Advanced Chronic Hepatitis C  
  Morgan TR, Ghany MG, Kim HY, Snow KK, Shiffman ML, De Santo JL, Lee WM, Di Bisceglie AM, Bonkovsky HL, Dienstag JL, Morishima C, Lindsay KL, Lok AS, and the HALT-C Tri..., Hepatology, 1/1/2010
• Complication Rate of Percutaneous Liver Biopsies Among Persons with Advanced Chronic Liver Disease in the HALT-C Trial  
  Seeff LB, Everson GT, Morgan TR, Curto TM, Lee WM, Ghany MG, Shiffman ML, Fontana RJ, Di Bisceglie AM, Bonkovsky HL, Dienstag JL, and the HALT-C Trial Group, Clin Gastroenterol Hepatol, 1/1/2010
• Occult hepatitis B virus infection in patients with isolated core antibody and HIV co-infection in an urban clinic in Johannesburg, South Africa  
  Firnhaber C, Viana R, Reyneke A, Schultze D, Malope B, Maskew M, Di Bisceglie AM, MacPhail P, Sanne I, Kew M, J Inf Dis, 1/1/2009
• Clinical, Virologic, Histologic, and Biochemical Outcomes after Successful HCV Therapy: a 5 year follow-up of 150 patients  
  George SL, Bacon BR, Brunt EM, Mihindukulasuriya KL, Hoffmann J, Di Bisceglie AM, Hepatology, 1/1/2009
• Evidence for action of ribavirin through the hepatitis C virus RNA polymerase  
  Cannon NA, Donlin MJ, Mayes LM, Lyra AC, Di Bisceglie AM, Tavis JE, J Viral Hepatitis, 1/1/2009
• Baseline characteristics and early on-treatment response predict the outcomes of two years telbivudine treatment of chronic hepatitis B  
  Zeuzem S Gane E, Liaw Y-F, Lim SG, Di Bisceglie AM et al, J Hepatol, 1/1/2009
• Evolution of Hepatic Steatosis in Patients with Advanced Hepatitis C: Results From The Halt-C Trial  
  Lok AS, Everhart JE, Chung RT, Kim H-Y, Everson GT, Hoefs JC, Greenson JK, Sterling RK, Lindsay KL, Lee WM, Di Bisceglie AM, Bonkovsky HL, Ghany MG, Morishima C and th..., Hepatology, 1/1/2009
• Mutations in the Hepatitis C Virus Core Gene Are Associated with Advanced Liver Disease and Hepatocellular Carcinoma  
  Fishman S, Di Bisceglie AM, Branch A, et al, Clin Cancer Res, 1/1/2009
• Re-treatment of patients with chronic hepatitis C who do not respond to peginterferon-a2b A randomized trial  
  Jensen DM, Marcellin P, Freilich B, Andreone P, Di Bisceglie AM et al, Ann Intern Med, 1/1/2009
• Variants in interferon-alpha pathway genes and response to pegylated interferon-alpha2a plus ribavirin for treatment of chronic hepatitis C virus infection in the hepa...  
  Welzel TM, Morgan TR, Bonkovsky HL, Naishadam D, Pfeiffer RM, Wright EC, Hutchinson AA, Crenshaw AT, Bashirova A, Carrington M, Dotrang M, Sterling RK, Lindsay KL, Fon..., Hepatology, 1/1/2009
• Effect of HCV RNA Suppression During Peginterferon Alfa-2a Maintenance Therapy On Clinical Outcomes in the HALT-C Trial  
  Shiffman ML, Morishima C, Dienstag JL, Lindsay KL, Hoefs JC, Lee WM, Wright EC, Naishadham D, Everson GT, Lok AS, Di Bisceglie AM, Bonkovsky HL, Ghany MG and the HALT-..., Gastroenterology, 1/1/2009
•  
  Mulligan EK, Germer JJ, Arens MQ, D'Amore KL, Di Bisceglie AM, Ledeboer NA, Moser MJ, Newman AC, O'Guin AK, Olivo PD, Podzorski DS, Vaughan KA, Yao JD, Elagin SA and J..., J Clin Microbiol, 1/1/2009
• Coffee Intake Is Associated with Lower Rates of Liver Disease Progression in Chronic Hepatitis C  
  Freedman ND, Everhart JE, Lindsay KL, Ghany MG, Curto TM, Shiffman ML, Lee WM, Lok AS, Di Bisceglie AM, Bonkovsky1 HL, Hoefs JC, Dienstag JL, Morishima1 C, Abnet CC, S..., Hepatology, 1/1/2009
• Clinical decisions Management of incidental hepatitis C virus infection HCV therapy with peginterferon and ribavirin  
  Di Bisceglie AM, N Engl J Med, 1/1/2009
• (Book review): "Curbside consultation of Hepatology; 49 Clinical Questions"  
  Di Bisceglie AM, Gastroenterology, 1/1/2009
• (Letter) Prolonged therapy for hepatitis C with low-dose peginterferon  
  Di Bisceglie AM, Wright E, Dienstag JL, N Engl J Med, 1/1/2009
• Management of posttransplant hepatitis C recurrence  
  Di Bisceglie AM, Gastroenterology & Hepatology, 1/1/2009
• Herbal Product Use by Persons Enrolled in the Hepatitis C Antiviral Long-Term Treatment against Cirrhosis (HALT-C) Trial  
  Seeff LB, Curto TM, Szabo G, Everson GT, Bonkovsky HL, Dienstag JL, Shiffman ML, Lindsay KL, Lok ASF, Di Bisceglie AM, Lee WM, Ghany MG and the HALT-C Trial Group, Hepatology, 1/1/2008
• The prevalence of hepatitis B co-infection in a South African urban government HIV clinic  
  Firnhaber C, Reyneke A, Schulze D, Malope B, Maskew M, MacPhail P, Sanne I, Di Bisceglie A, S Afr Med J, 1/1/2008
• Improved outcomes in patients with hepatitis C with difficult-to-treat characteristics: Randomized study of higher doses of peginterferon a-2a and ribavirin  
  Fried MW, Jensen D, Rodriguez-Torres M, Nyberg L, Di Bisceglie AM, Morgan T, Pockros P, Lin A, Cupelli L, Duff F, Wang K, Nelson D, Hepatology, 1/1/2008
• Prolonged Therapy Of Advanced Chronic Hepatitis C With Low Dose Peginterferon  
  Di Bisceglie AM, Shiffman ML, Everson GT, Lindsay KL, Everhart JE, Wright EC, Lee WM, Lok AS, Bonkovsky HL, Morgan TR, Ghany MG, Morishima C, Snow KK, Dienstag JL for ..., N Engl J Med, 1/1/2008
• Comparative analysis of nearly full-length hepatitis C virus quasispecies from patients experiencing viral breakthrough during antiviral therapy: clustered mutations i...  
  Xu Z, Fan X, Xu Y, Di Bisceglie AM, J Virol, 1/1/2008
• Serum activity of alanine aminotransferase (ALT) as an indicator of health and disease  
  Kim WR, Flamm SL, Di Bisceglie AM, Bodenheimer HC, Hepatology, 1/1/2008
• Design and endpoints of clinical trials in hepatocellular carcinoma  
  Llovet, Di Bisceglie AM, Bruix J, Kramer BS, Lencioni R, Zhu AX, Sherman M, Schwartz M, Lotze M, Talwakar J, Gores GJ for the Panel of Experts in HCC-Design Clinical T..., J Natl Cancer Inst, 1/1/2008
• Health-related quality of life in patients with chronic hepatitis C and advanced fibrosis  
  Bonkovsky HL, Snow KK, Malet PF, Back-Madruga C, Fontana RJ, Sterling RK, Kulig CC, Di Bisceglie AM, Morgan TR, Dienstag JL, Ghany MG, Gretch DR, HALT-C Trial Group, J Hepatol, 1/1/2007
• Separation of near full-length hepatitis C virus quasispecies variants from complex population  
  Zhou D, Fan X, Tan D, Xu Y, Tavis JE, Di Bisceglie AM, J Virological Methods, 1/1/2007
• Early virologic response after peginterferon alfa-2A plus ribavirin or peginterferon alfa-2b plus ribavirin treatment in patients with chronic hepatitis C  
  Di Bisceglie AM, Ghalib RH, Hamzeh FM, Rustgi VK, J Viral Hepatitis, 1/1/2007
• Sequence diversity in the full-length hepatitis C virus coding region correlates with response to therapy  
  Donlin MJ, Cannon NA, Yao E, Li J, Wahed A, Taylor MW, Belle SH, Di Bisceglie AM, Aurora R, Tavis JE for the Virahep-C Study Group, J Virol, 1/1/2007
• Telbivudine versus Lamivudine for Patients with HBeAg-positive Chronic Hepatitis B: Results of a Global Phase III Comparative Trial  
  Lai CL, Gane E, Liaw Y-F, Thongsawat S, Wang Y, Chen Y, Heathcote J, Rasenack J, Bzowej N, Di Bisceglie AM, Zeuzem S, Naoumov N, Moon YM, Goodman Z, Chao G, Fielman B,..., New Engl J Med, 1/1/2007
• Hepatocyte senescence in end-stage chronic liver disease: a study of cyclin-dependent kinase inhibitor p21 in liver biopsies as a marker for progression to hepatocellu...  
  Brunt EM, Walsh SN, Hayashi PH, LaBundy J, Di Bisceglie AM, Liver International, 1/1/2007
• Differences between Caucasian, African American and Hispanic patients with primary biliary cirrhosis in the United States  
  Peters MG, Di Bisceglie AM, Kowdley KV, Flye NL, Luketic VA, Munoz SJ, Garcia-Tsao G, Boyer TD, Lake JR, Bonacini M, Combes B, Hepatology, 1/1/2007
• Cost-effectiveness of entecavir versus lamivudine in HBeAg-positive chronic hepatitis B based no a 2-year clinical trial  
  Veenstra DL, Iloeje JH, Sullivan SD, Tafesse E, Clark L, Di Bisceglie AM, Kowdley KV, Gish RG, Pharmacoeconomics, 1/1/2007
• Diagnostic and therapeutic approach to hepatocellular carcinoma in the USA  
  Di Bisceglie AM, Befeler AS, Hepatology Research, 1/1/2007
• Diagnostic and therapeutic approach to hepatocellular carcinoma in the USA (suppl 2)  
  Di Bisceglie AM, Befeler AS, Hepatology Research, 1/1/2007
• Pharmacokinetics, pharmacodynamics and hepatitis C viral kinetics during antiviral therapy: The null responder  
  Di Bisceglie AM, Fan X, Chambers T, Strinko J, J Med Virol, 1/1/2006
• Comparison of liver biopsy and non-invasive methods for diagnosis of hepatocellular carcinoma  
  Bialecki ES, Ezenekwe AM, Brunt EM, Collins BT, Ponder TB, Bieneman BK, Di Bisceglie AM, Clin Gastro Hepatol, 1/1/2006
• The Prevalence and Risk Factors Associated with Esophageal Varices in Subjects with Hepatitis C and Advanced Fibrosis  
  Sanyal AJ, Fontana RJ, Di Bisceglie AM, Everhart JE, Doherty MC, Everson GT, Donovan JA, Malet PF, Mehta S, Sheikh MY, Reid AE, Ghany MG, Gretch DR, The HALT-C Trial G..., GI Endoscopy, 1/1/2006
• HCV RNA detection by TMA during the Hepatitis C Antiviral Long-Term Treatment Against Cirrhosis (HALT-C) Trial  
  Morishima C, Morgan TR, Everhart JE, Wright EC, Shiffman ML, Everson GT, Lindsay KL, Lok ASF, Bonkovsky HL, Di Bisceglie AM, Lee WM, Dienstag JL, Ghany MG, Gretch DR a..., Hepatology, 1/1/2006
• Efficient amplification and cloning of near full-length hepatitis C virus genome from clinical samples  
  Fan X, Xu Y, Di Bisceglie AM, Biochem Biophys Res Com, 1/1/2006
• Hepatic steatosis in hepatitis C: Comparison of diabetic and non-diabetic patients in the HALT-C Trial  
  Lok ASF, Everhart JE, Chung RT, Padmanabhan L, Greenson JK, Shiffman ML, Everson GT, Lindsay KL, Bonkovsky HL, Di Bisceglie AM, Lee WM, Morgan TR, Ghany MG, Miroshima ..., Clin Gastro Hepatol, 1/1/2006
• Spontaneous retroperitoneal and rectus muscle hemorrhage as a potentially lethal complication of cirrhosis  
  Di Bisceglie AM, Richart JM, Liver International, 1/1/2006
• Roles of iron and HFE mutations on severity and response to therapy during retreatment of advanced chronic hepatitis C  
  Bonkovsky HL, Naishadham D, Nash SR, Rogers TE, Banner BF, Sterling RK, Donovan JA, Fontana RJ, Di Bisceglie AM, Ghany MG, Morishima C; HALT-C Trial Group, Gastroenterology, 1/1/2006
• Impact of Disease Severity on Outcome of Antiviral Therapy for Chronic Hepatitis C: Lessons from the HALT-C Trial  
  Everson GT, Hoefs JC, Seeff LB, Bonkovsky HL, Naishadham D, Shiffman ML, Kahn JA, Lok ASF, Di Bisceglie AM, Lee WM, Dienstag JL, Ghany MG, Morishima C, and the HALT-C ..., Hepatology, 1/1/2006
• The progression of hepatitis B-and C-infectious to chronic liver disease and hepatocellular carcinoma: Presentation, diagnosis, screening, prevention and treatment of ...  
  Hayashi PH, Di Bisceglie AM, Infect Dis Clinic N Am, 1/1/2006
• Associations among clinical, histologic, immunologic and viral quasispecies measures in advanced chronic hepatitis C: Baseline analysis of the HALT-C trial  
  Rothman AL, Morishima C, Bonkovsky HL, Polyak SJ, Ray R, Di Bisceglie AM, et al, Hepatology, 1/1/2005
• Quasispecies heterogeneity within the E1/E2 region as a pretreatment variable during pegylated interferon therapy of chronic hepatitis C virus infection  
  Chambers TJ, Fan X, Droll DA, Hembrador E, Slater T, Nickells M, Dustin LB, Di Bisceglie AM, J Virology, 1/1/2005
• The safety of intra-abdominal surgery in cirrhotics: A predictive model using the MELD score and pre-operative hemoglobin  
  Befeler AS, Palmer DE, Hoffman M, Longo W, Solomon H, Di Bisceglie AM, Arch Surg, 1/1/2005
• Serum alpha-fetoprotein levels in patients with advanced hepatitis C-associated liver disease without hepatocellular carcinoma: Results from the Halt-C Trial  
  Di Bisceglie AM, Sterling RK, Chung RT, Everhart JE, Dienstag JL, Bonkovsky HL, Wright EC, Everson GT, Lindsay KL, Lok ASF, Lee WM, Morgan TR, Ghany MG, Gretch DR and ..., J Hepatology, 1/1/2005
• Comparison of amplification enzymes for hepatitis C virus quasispecies analysis  
  Polyak SJ, Sullivan DG, Austin MA, Dai JY, Shuhart MC, Lindsay KL, Bonkovsky HL, Di Bisceglie AM, Lee WM, Morishima C, Gretch DR and the HALT-C Trial group, Virology Journal, 1/1/2005
• Plasma chemokine levels correlate with the outcome of antiviral therapy in hepatitis C patients  
  Butera D, Marukian S, Iwamaye AE, Hembrador E, Chambers TJ, Di Bisceglie AM, Charles ED, Talal AH, Jacobson IM, Rice CM, Dustin LB, Blood, 1/1/2005
• Methotrexate (MTX) plus ursodeoxycholic acid (UDCA) in the treatment of primary biliary cirrhosis (PBC)  
  Combes B, Emerson SS, Flye NL, Munoz SJ, Luketic VA, Mayo ML, McCashland TM, Zetterman RK, Peters MG, Di Bisceglie AM, et al, Hepatology, 1/1/2005
• Diagnosis of hepatocellular carcinoma  
  Bialecki ES, Di Bisceglie AM, HPB, 1/1/2005
• Clinical presentation and natural course of hepatocellular carcinoma  
  Bialecki ES, Di Bisceglie AM, European J Gastro Hepatol, 1/1/2005
• The progression of hepatitis B-and C-infections to chronic liver disease and hepatocellular carcinoma: Presentation, screening, prevention, and treatment of hepatocell...  
  Hayashi PH, Di Bisceglie AM, Med Clin N Am, 1/1/2005
• The progression of hepatitis B-and C-infections to chronic liver disease and hepatocellular carcinoma: Presentation, screening, prevention, and treatment of hepatocell...  
  Hayashi PH, Di Bisceglie AM, Med Clin N Am, 1/1/2005
• Pretransplant treatments for hepatocellular carcinoma: Do they improve outcomes?  
  Di Bisceglie AM, Liver Transplant, 1/1/2005
• Distribution of hepatitis B virus (HBV) genotypes among patients with acute viral hepatitis (letter)  
  Lyra AC, Pinho JRR, Mello IMVGC, Malta F deM, Gomes MMS, Di Bisceglie AM, Lyra LGC, Carrilho FJ, da Silva LC, J Clin Gastroenterol, 1/1/2005
• (Book review) Hepatocellular cancer: Diagnosis and treatment  
  Di Bisceglie AM, Gastroenterology, 1/1/2005
• Does bare-stent TIPS increase the risk of hepatocellular carcinoma in patients with cirrhosis? (Commentary)  
  Di Bisceglie AM, Nature Clinical Practice: Gastroenterology and Hepatology, 1/1/2005
• Histological changes after the use of mycophenolate mofetil in autoimmune hepatitis: A case report  
  Brunt EM, Di Bisceglie AM, Human Pathology, 1/1/2004
• HCV E2 glycoprotein: Mutagenesis of the N-linked glycosylation sites and effects on protein expression and secretion  
  Slater-Handshy T, Droll D A, Fan X, Di Bisceglie AM, and Chambers T, Virology, 1/1/2004
• Risk factors for hepatocellular carcinoma in patients with cirrhosis  
  Sarbah SA, Gramlich T, Younoszai A, Osmack P, Goormastic M, Grosso L, Cooper JN, Di Bisceglie AM, Seneca R, Younossi ZM, Dig Dis Sci, 1/1/2004
• Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment  
  Shiffman ML, Di Bisceglie AM, Lindsay KL, Morishima C, Wright EC, Everson GT, Lok AS, Morgan TR, Bonkovsky HL, Lee WM, Dienstag JL, Ghany MG, Goodman ZD, Everhart JE, ..., Gastroenterology, 1/1/2004
• A descriptive study of the relationship between mood disorders and hepatitis C treatment compliance: Does nursing play a role?  
  Strinko JM, Di Bisceglie AM, Hoffmann JA, Issues Mental Health Nurs, 1/1/2004
• Evolution of the HALT-C trial: Pegylated interferon as maintenance therapy for chronic hepatitis C in previous interferon nonresponders  
  Lee WM, Dienstag JL, Lindsay KL, Lok AS, Bonkovsky HL, Shiffman ML, Everson GT, Di Bisceglie AM, Morgan TR, Ghany MG, Morishima C, Wright EC, Everhart JE, and the HALT..., Contr Clin Trials, 1/1/2004
• CD81 binding regions of hepatitis C virus remain conserved after liver transplantation  
  Lyra AC, Fan X, Di Bisceglie AM, Braz J Infect Dis, 1/1/2004
• Long term follow up of bone mineral density in patients with primary biliary cirrhosis  
  Di Bisceglie AM, Loyet M, Peters M, Minerva Med, 1/1/2004
• What every hepatologist should know about endocrinology: Obesity, diabetes, and liver disease (editorial)  
  Di Bisceglie AM, Gastroenterology, 1/1/2004
• Join now to see all

Books/Book Chapters

• Schiff's Diseases of The Liver 
  Chapter: Benign tumors, nodules and cystic diseases of the liver. 
  Page 937 - 976Di Bisceglie AM, Befeler ASEditors: Schiff ER, Maddrey WC, Sorrell MF.Wiley-BlackwellEdition 11th,2012
• Cancer: Principles and Practice of Oncology 
  Chapter: Cancer of the Liver. 
  Page 997 - 1018Bartlett DL, Di Bisceglie AM, Dawson LAEditors: DeVita, Lawrence and Rosenberg.Lippincott Williams and Wilkins, PhiladelphiaEdition 9th,2011
• Liver Cirrhosis and Its Development. Falk Symposium 
  Chapter: Hepatitis C-evolving therapeutic strategies. 
  Page 156 - 160Di Bisceglie AMEditors: Boyer JL, Blum HE, Maier K-P, Sauerbruch T, Stalder GA.2011
• Sleisinger and Fordtran's Gastrointestinal and Liver Disease 
  Chapter: Tumors and cysts of the liver. 
  Page 1569 - 1592Di Bisceglie AM, Befeler ASEditors: Feldman M, Friedman LS, Brandt LJ.Saunders Elsevier, PhiladelphiaEdition 9th,2010
• DeVita, Hellman and Rosenberg's Cancer: Principles and Practice of Oncology 
  Chapter: Cancer of the liver. 
  Page 1129 - 1156Bartlett DL, Di Bisceglie AM, Dawson LAWolters Kluwer/Lippincott Williams and Wilkins, Philadelphia2008
• Internal Medicine. Just the Facts 
  Chapter: Diseases of the pancreas. 
  Page 343 - 347Di Bisceglie AMEditors: Schmitz PG, Martin KJ.McGraw Hill, New York2008
• Internal Medicine. Just the Facts 
  Chapter: Liver and biliary diseases. 
  Page 338 - 342Di Bisceglie AMEditors: Schmitz PG, Martin KJ.McGraw Hill, New York2008
• Infectious Disease. A Scientific American Reader 
  Chapter: The unmet challenge of hepatitis C. 
  Page 47 - 57Di Bisceglie AM and Bacon BRUniversity of Chicago Press, Chicago2008
• Schiff's Diseases of the Liver 
  Chapter: Nodular and cystic lesions. 
  Page 1231 - 1251Di Bisceglie AM, Befeler ASLippincott Williams & Wilkins, PhiladelphiaEdition 10th,2007
• Comprehensive Clinical Hepatology 
  Chapter: Hepatitis C. 
  Page 235 - 248Di Bisceglie AMMosby Elsevier, PhiladelphiaEdition 2nd,2006
• Comprehensive Clinical Hepatology 
  Chapter: Imaging of the liver. 
  Page 123 - 136Bieneman BK, Di Bisceglie AMMosby Elsevier, PhiladelphiaEdition 2nd,2006
• Handbook of Management Issues in Hepatitis C 
  Chapter: Screening for hepatocellular carcinoma. 
  Page 119 - 130Bialecki E and Di Bisceglie AM2005
• Management Issues in Hepatitis C Infection 
  Chapter: Screening for hepatocellular carcinoma. 
  Page 118 - 121Bialecki E, Di Bisceglie AMEditors: McHutchison J.Science Press, London2004
• Handbook of Liver Disease 
  Chapter: Hepatic tumors. 
  Page 339 - 348Di Bisceglie AMEditors: Friedman LS, Keeffe EB.Churchill Livingstone, PhiladelphiaEdition 2nd,2004
• Digestive Disease Self-Evaluation Program (DDSEP III) for the American Gastroenterological Association 
  Chapter: Viral Hepatitis. 
  Page 271 - 288Di Bisceglie AM2004
• Viral Hepatitis 
  Chapter: Hepatitis and hepatocellular carcinoma. 
  Page 133 - 138Di Bisceglie AMEditors: Buti M, Esteban R.Accion Medica SA, Madrid2003
• Hepatitis C-Current Diagnosis and Emerging Treatment Options 
  Page 1 - 16Di Bisceglie AMThomson PDR, Montvale, NJ2003
• Atlas of the Liver 
  Chapter: Tumors of the liver. 
  Page 287 - 301Di Bisceglie AMEditors: Maddrey WC and Feldman M.Current Medicine, Philadelphia2003
• Digestive Disease Self-Evaluation Program (DDSEP II) for the American Gastroenterological Association 
  Chapter: Viral Hepatitis. 
  Di Bisceglie AM2002
• Viruses and Liver Cancer 
  Chapter: Treatment of hepatocellular carcinoma. 
  Page 161 - 172Befeler A and Di Bisceglie AMEditors: Tabor E.Elsevier Science B.V., The Netherlands2002
• Textbook of Viral Hepatitis 
  Chapter: Treatment in patients with normal ALT and/or minimal histologic lesions. 
  Page 158 - 167Lyra AC and Di Bisceglie AMEditora Atheneu, Sao PauloEdition 1st,2002
• Therapies for Viral Hepatitis 
  Chapter: Compartmentalization of hepatitis C viral quasispecies. 
  Page 123 - 130Fan X, Castro-Lyra A, Di Bisceglie AMEditors: Schinazi RF, Rice C, and Sommadossi J-P.Elsevier Science, The Netherlands2002
• Clinics in Liver Disease 
  Chapter: Liver Tumors. 
  Di Bisceglie, AMW.B. Saunders Co., Philadelphia2001
• Hepatitis C 
  Chapter: Hepatitis and hepatocellular carcinoma. 
  Page 265 - 275Di Bisceglie AMAcademic Press2000
• Liver Disease: Diagnosis and Management 
  Chapter: Management of chronic viral hepatitis. 
  Page 98 - 106Di Bisceglie AM, Hoofnagle JHEditors: Di Bisceglie AM, Bacon BR.Churchill Livingstone, New York1999
• Therapy of Digestive Disorders: A Companion to Sleisenger and Fordtran's Gastrointestinal and Liver Disease 
  Chapter: Management of tumors of the liver. 
  Page 421 - 428Di Bisceglie AM and Richart JMEditors: Wolfe MM.1999
• Digestive Disease Self-Evaluation Program (DDSEP) for the American Gastroenterological Association 
  Chapter: Viral Hepatitis. 
  Di Bisceglie AM1999
• Treatment of Liver Diseases 
  Chapter: Iron and viral hepatitis. 
  Page 307 - 310Di Bisceglie AMEditors: Arroyo V, Bosch J, Bruguera M, Rodes J, Sanchez Tapias JM.Masson, Barcelona1999
• Therapy of Digestive Disorders 
  Chapter: Management of tumors of the liver. 
  Page 901 - 904Stribling R, Martin P, Di Bisceglie AMEditors: Wolfe MM.1999
• AIDS Therapy 
  Chapter: Viral Hepatitis. 
  Page 516 - 529Di Bisceglie AMEditors: Dolin R, Masur H, Saag M.Dolin R, Masur H, Saag M1999
• Schiff's Diseases of the Liver 
  Chapter: Malignant neoplasms of the liver. 
  Page 1281 - 1303Di Bisceglie AMEditors: Schiff ER, Maddrey WC, Sorrell M.Lippincott-RavenEdition 8th,1999
• Handbook of Liver Diseases 
  Chapter: Hepatic tumors. 
  Page 361 - 372Di Bisceglie AMEditors: Friedman LS, Keefe E.Churchill Livingstone, Edinburgh1998
• Clinical and Pathological Correlations in Liver Disease: Approaching the Next Millennium 
  Chapter: The liver mass-clinical. 
  Page 97 - 102Di Bisceglie AMEditors: Bloomer JR, Goodman ZD, Ishak KG.1998
• Viral Hepatitis and Liver Diseases; Proceedings of the IXth Triennial Int'l Symposium on Viral Hepatitis and Liver Diseases 
  Chapter: Hepatitis C: Clinical aspects and therapy. 
  Page 916 - 918Di Bisceglie AM, Rakela JEditors: Rizetto M.1997
• Cancer Rates and Risks 
  Chapter: Liver. 
  Page 155 - 157Di Bisceglie AM, Tabor EEditors: National Institutes of Health, National Cancer Institute.Edition 4th,1996
• Hepatology 
  Chapter: Chronic viral hepatitis. 
  Page 1299 - 1329Di Bisceglie AM, Hoofnagle JHEditors: Zakim D, Boyer T.PhiladelphiaEdition 3rd,1996
• Current Practice of Medicine 
  Chapter: Tumors of the liver. 
  Page 1 - 8Di Bisceglie AMEditors: Bone RC.1996
• Viral Hepatitis 
  Chapter: Hepatitis D virus. 
  Page 217 - 238Di Bisceglie AMEditors: Willson R.Marcel Dekker, New York1996
• Gastroenterology and Hepatology: The Comprehensive Visual Reference (The Liver) 
  Chapter: Tumors of the liver. 
  Page 2 - 13Di Bisceglie AM, Buetow PCEditors: Maddrey WC, Feldman M.1995
• Treatments in Hepatology 
  Chapter: New treatments for chronic hepatitis B. 
  Page 203 - 206Di Bisceglie AMEditors: Arroyo V, Bosch J, Rodes J.Masson, S.A., Barcelona1995
• Viral Hepatitis and Liver Disease 
  Chapter: The physical state of the negative strand of hepatitis C virus RNA in serum of patients with chronic hepatitis C. 
  Page 147 - 149Shindo M, Di Bisceglie AM, Akatsuka T, Fong T-L, Donets M, Hoofnagle JH, Feinstone SMEditors: Nishioka K, Suzuki H, Mishiro S, Oda T.Springer-Verlag, New York1994
• Clin Gastroenterol 
  Chapter: Viral hepatitis and hepatocellular carcinoma. 
  Page 567 - 579Sallie R, Di Bisceglie AMEditors: Martin P, Friedman L.1994
• Biologic Agents in Autoimmune Diseases 
  Chapter: Alpha interferon therapy for chronic viral hepatitis: From bench to approval. 
  Page 65 - 69Di Bisceglie AM, Hoofnagle JHEditors: Strand V.Arthritis Foundation, Atlanta1994
• Viral Hepatitis and Liver Disease 
  Chapter: Hepatitis C viral RNA and hepatic cytokine expression in chronic hepatitis C: The effect of alpha interferon therapy. 
  Page 627 - 630Shindo M, Hoofnagle JH, Di Bisceglie AMEditors: Nishioka K, Suzuki H, Mishiro S, Oda T.Springer-Verlag, New York1994
• Viral Hepatitis and Liver Disease 
  Chapter: The physical state of the negative strand of HCV RNA in serum. 
  Page 147 - 149Shindo M, Di Bisceglie AM, Akatsuka T, Fong TL, Donets M, Hoofnagle JH, Feinstone SMEditors: Nishioka K, Suzuki H, Mishiro S, Oda T.Springer-Verlag, New York1994
• Viral Hepatitis and Liver Disease 
  Chapter: Changes in levels of HCV-RNA and hepatitis C viral antigen associated with interferon-alpha therapy of chronic hepatitis C. 
  Page 610 - 613Di Bisceglie AM, Shindo M, Krawczynski K, Hoofnagle JHEditors: Nishioka K, Suzuki H, Mishiro S, Oda T.Springer-Verlag, New York1994
• Viral Hepatitis 
  Chapter: Epidemiology and diagnosis of hepatitis D virus. 
  Page 351 - 362Di Bisceglie AMEditors: Zuckerman AJ, Thomas HC.Churchill LivingstoneEdition 1st,1993
• Hepatitis Delta Virus 
  Chapter: Therapy of chronic delta hepatitis: An overview. 
  Page 337 - 343Hoofnagle JH, Di Bisceglie AMEditors: Bonino F, Taylor J, Hadziyannis S.New York1993
• Viral Hepatitis 
  Chapter: Natural history of hepatitis D virus. 
  Page 341 - 350Conjeevaram H, Di Bisceglie AMEditors: Zuckerman AJ, Thomas HC.Churchill LivingstoneEdition 1st,1993
• The Liver in Systemic Disease 
  Chapter: Metabolic diseases of the liver. 
  Page 167 - 189Fried MW, Di Bisceglie AMEditors: Rustgi VK, Van Thiel DH.Raven Press, New York1993
• Hepatitis Delta Virus 
  Chapter: Prolonged alpha interferon therapy for chronic delta hepatitis: Effect on liver histopathology. 
  Page 365 - 371Kleiner D, Di Bisceglie AM, Axiotis CA, Hoofnagle JHEditors: Bonino F, Taylor J, Hadziyannis S.New York1992
• Viral Hepatitis and Liver Disease 
  Chapter: Loss of hepatitis B surface antigen (HBsAg) following treatment of chronic hepatitis B with alpha interferon. 
  Page 639 - 640Korenman JC, Baker BL, Waggoner JG, Di Bisceglie AM, Hoofnagle JHEditors: Hollinger B, Lemon SM, Margolis HS.Williams and Wilkins, Baltimore1991
• Progress and Prospects in Viral Hepatitis 
  Chapter: Detection of hepatitis delta virus RNA by in situ hybridization: Virological implications. 
  Page 367 - 370Negro F, Pacchioni D, Di Bisceglie AM, Gerin JL, Bussolati G, Bonino FEditors: Schiraldi O, Pastore G, Dentico P.Gerni Editori, San Severo1991
• Viral Hepatitis and Liver Disease 
  Chapter: Detection of hepatitis C viral RNA by the polymerase chain reaction. 
  Page 374 - 375Cristiano K, Baker B, Di Bisceglie AM, Feinstone SMEditors: Hollinger B, Lemon SM, Margolis HS.Williams and Wilkins, Baltimore1991
• Viral Hepatitis and Liver Disease 
  Page 434 - 435Krawczynski K, Kuo G, Di Bisceglie AM, Bradley D, Houghton M, Alter M, Ebert JEditors: Hollinger B, Lemon SM, Margolis HS.Williams and Wilkins, Baltimore1991
• Hepatocellular Carcinoma in North America 
  Chapter: Chronic viral hepatitis and hepatocellular carcinoma. 
  Page 127 - 138Di Bisceglie AMEditors: Tabor E, Di Bisceglie AM, Purcell RH.Portfolio Publishing, Houston1991
• Viral Hepatitis and Liver Disease 
  Chapter: Treatment of chronic non A, non B (type C) hepatitis. 
  Page 623 - 626Di Bisceglie AM. In, Hollinger B, Lemon SM, Margolis HSEditors: Hollinger B, Lemon SM, Margolis HS.Williams and Wilkins, Baltimore1991
• Hepatocellular Carcinoma in North America 
  Chapter: Radiologic findings in hepatocellular carcinoma: The National Institutes of Health Experience. 
  Page 255 - 272Feuerstein IM, Chow CK, Miller DL, Carrasquillo JA, Lotze MT, Di Bisceglie AMPortfolio Publishing, Houston1991
• Viral Hepatitis and Liver Disease 
  Chapter: The significance of antibody hepatitis C virus in patients with chronic hepatitis B. 
  Page 447 - 448Fong TLF, Di Bisceglie AM, Waggoner JG, Banks SM, Hoofnagle JHEditors: Hollinger B, Lemon SM, Margolis HS.Williams and Wilkins, Baltimore1991
• Viral hepatitis C, D, E 
  Page 151 - 156Hoofnagle JH, Di Bisceglie AMEditors: Shikata T, Purcell RH, Uchida T.Elsevier, Amsterdam1991
• Hepatitis. Viral and Drug Induced 
  Chapter: Delta hepatitis. 
  Page 19 - 26Di Bisceglie AMEditors: Perrillo RP.National Health Labs, La Jolla1991
• Antiviral Agents and Viral Diseases of Man 
  Chapter: Antiviral therapy of viral hepatitis. 
  Page 415 - 459Hoofnagle JH, Di Bisceglie AMEditors: Galasso Whitley, Merigan.Edition 3rd,1990
• Viral Hepatitis and Liver Disease 
  Chapter: Therapy of chronic viral hepatitis: chronic hepatitis D and non A, non B hepatitis. 
  Page 823 - 830Hoofnagle JH, Di Bisceglie AMEditors: Zuckerman AJ.Alan R. Liss, New York1988
• Viral Hepatitis and Liver Disease 
  Chapter: Alpha interferon treatment of patients with decompensated chronic type B hepatitis. 
  Page 840 - 843Kassianides, Di Bisceglie AM, Hoofnagle JH, Mullen KD, Peters M, Rustgi VK, Jones DB, Lisker-Melman M, Park Y, Waggoner J, Jones EAEditors: Zuckerman AJ.Alan R. Liss, New York1988
• Viral Hepatitis and Liver Disease 
  Chapter: Effect of recombinant human gamma interferon therapy on immune function in patients with chronic type B hepatitis. 
  Page 868 - 871Editors: Zuckerman AJ.Alan R. Liss, New York1988
• Cancer: Principles and practice of Oncology (Updated) 
  Chapter: Hepatitis B virus infection and hepatocellular carcinoma. Etiologic relationship and clinical implications. 
  Page 1 - 10Di Bisceglie AM and Hoofnagle JHEditors: DeVita VT, Hellman S, Rosenberg SA.J.B. Lippincott Co.1987
• Schiff's Diseases of the Liver 
  Chapter: Cystic and nodular diseases of the liver. 
  Page 1149 - 1168Di Bisceglie AM and Befeler ASEditors: Schiff ER, Sorrell MF, Maddrey WC.Lippincott Williams and Wilkins, PhiladelphiaEdition 9th,
• RT-PCR Protocols; Methods in Molecular Biology. Vol 630 
  Chapter: RT-PCR amplification and cloning of large viral sequences. 
  Page 130 - 149Fan X, Di Bisceglie AMEditors: Nicola King.Edition 2nd,
• Join now to see all

Abstracts/Posters

• SAPPHIRE II: Phase 3 Placebo-Controlled Study of Interferon-Free, 12-Week Regimen of ABT-450/r/ABT-267, ABT-333, and Ribavirin in 394 Treatment-Experienced Adults With...
  S Zeuzem, I Jacobson, T Baykal, RT Marinho, F Poordad, M Bourliere, M Sulkowski, H Wedemeyer, E Tam, P Desmond, D Jensen, AM Di Bisceglie, P Varunok, T Hassanein, J Xi..., EASL, 1/1/2014
• All Oral Fixed-dose Combination Sofosbuvir/Ledipasvir with or without Ribavirin for 12 or 24 Weeks in Treatment-Experienced Genotype 1 HCV-infected Patients: The Phase...
  Paul Kwo, Rajender K. Reddy, Paul Pockros, Adrian M. Di Bisceglie, Sanjeev Arora, Jenny C. Yang, Hadas Dvory-Sobol, Yanni Zhu, Phil S. Pang, William T. Symonds, John G..., Digestive Diseases Week, 1/1/2014
• Safety of ABT-450/r/Ombitasvir + Dasabuvir With or Without Ribavirin in HCV Genotype 1-infected Patients: Results From Phase 2 and Phase 3 Trials.
  . Fried MW, Di Bisceglie AM, et al, Hepatology, 1/1/2014
• SVR12 Rate of 95.7% in 209 HCV Genotype 1-Infected Null Responders Treated With ABT-450/r/Ombitasvir and Dasabuvir With or Without Ribavirin.
  Jacobson IM< DuFour J-F, Enejosa J, de Knegt RJ, Ferenci P, Reynaert H, Di Bisceglie AM et al, Hepatology, 1/1/2014
• ABT-450/r/Ombitasvir + Dasabuvir With or Without Ribavirin in HCV Genotype 1-infected Patients with History of Depression or Bipolar Disorder: Pooled Analysis of Effic...
  Nelson DR, Reddy KR, Di Bisceglie AM et al, Hepatology, 1/1/2014
• Safety and Efficacy of Sofosbuvir (SOF) in Combination with Simeprevir (SIM) + Ribavirin (RBV) in Patients with Genotype 1: Interim Results of a Prospective, Observati...
  Sulkowski MS, Vargas HE, Di Bisceglie AM et al, Hepatology, 1/1/2014
• Virologic Outcomes and Adherence to Treatment Algorithms in a Longitudinal Study of Patients with Chronic Hepatitis C Treated with Boceprevir (BOC) or Telaprevir (TVR)...
  Di Bisceglie AM, Kuo A, Rustgi VK et al, AASLD, 11/1/2013
• Estimated impact of screening and antiviral treatment on prevention of HBV reactivation associated with cancer chemotherapy.
  Desai RJ, Schnitzler MA, Di Bisceglie AM, AASLD, 11/1/2013
• Combination of the NS5A Inhibitor, GS-5885, the NS3 Protease Inhibitor, GS-9451, and Pegylated Interferon Plus Ribavirin in Treatment Experienced Patients with Genotyp...
  Everson GT, Di Bisceglie A, Vierling JM et al, J Hepatol, 1/1/2013
• Phase II HCVac Study of TG4040 immunotherapeutic in combination with PegIFNalpha2a and ribavirin in genotype 1 CHC treatment naive patients: SVR24 Final Results.
  Wedemeyer H, Janczewska Kazek E, Mazur W, Stanciu C, Habersetzer F, Carreno V, Di Bisceglie AM et al, J Hepatol, 1/1/2013
• HCV-TARGET: A Longitudinal, Observational Study Of North American Patients With Chronic Hepatitis C (HCV) Treated With Boceprevir Or Telaprevir.
  Fried MW, Reddy KR, Di Bisceglie AM et al, J Hepatol, 1/1/2013
• HCV Treatment Selection and Duration Decision-Making: Real-World Issues with HCV RNA and HCV Genotype Assays Used in Clinical Practice.
  MW Fried, M Vainorius, KR Reddy, AM Di Bisceglie, DM Jensen, IM Jacobson, M Sulkowski, N Terrault, K Bergquist, TG Stewart, JA Peter, and DR Nelson for the HCV-TARGET ..., Global Antiviral Journal; HEP DART, 1/1/2013
• Anemia had no effect on efficacy outcomes in treatment-naive patients who received telaprevir-based regimen in the ADVANCE and ILLUMINATE phase 3 studies.
  Poordad F, Sulkowski M, Reddy R, Di Bisceglie AM, Zeuzem S, Afdhal N, Bengtsson L, Wright CI, Kauffman RS, Adda N, Can J Gastro; Digestive Diseases Week 2011, 1/1/2012
• Sustained virologic response rates and viral resistance profiles were similar in patients treated with a telaprevir-based regimen regardless of liver fibrosis stage.
  Marcellin P, Sullivan J, Fried MW, Kieffer TL, Dusheiko GM, Martin EC, Nelson DR, Di Bisceglie AM et al, Can J Gastro; Hepatology, 1/1/2012
• Vx-222/telaprevir in combination with peginterferon-alfa-2A and ribavirin in treatment-naive genotype 1 HCV patients treated for 12 weeks: Zenith study, SVR12 interim ...
  Nelson DR, Gane EJ, Jaconson IM, Di Bisceglie AM et al, Can J Gastro; Hepatology, 1/1/2012
• Telaprevir in combination with peginterferon alfa-2A and ribavirin: Analyses of pre-defined subpopulations in the pahse 3 ADVANCE trial.
  Marcellin P, Jaconson I, Zeuzem S, Bzowej N, Muir AJ, Dusheiko G, Reddy R, Adda N, Bengtsson L, Kauffman RS, George S, Di Bisceglie AM, J Hepatology, 1/1/2011
• Anemia had no effect on efficacy outcomes in treatment-naive patients who received telaprevir-based regimen in the ADVANCE and Illuminate phase 3 studies.
  Sulkowski MS, Reddy R, Afdhal NH, Di Bisceglie AM et al, J Hepatology, 1/1/2011
• Vx-222 with TVR alone or in combination with peginterferon alfa-2a and ribavirin in treatment-naive patients with chronic hepatitis C: Zenith study interim results.
  Di Bisceglie AM et al, J Hepatology, 1/1/2011
• Telaprevir in combination with peginterferon alfa-2a and ribavirin: analyses of pre-defined subpopulations in the phase 3 ADVANCE trial.
  Di Bisceglie AM, Dusheiko GM, Muir AJ, Zeuzem S, Marcellin P, Bzowej NH, Jacobson IM, Adda N, Bengtsson L, Kauffman RS, George S, Reddy R, Digestive Diseases Week, 1/1/2011
• Patient Mortality and Liver Transplantation during the HALT-C Trial: Relationship to Chronic Liver Disease and Interferon Therapy.
  Di Bisceglie AM, Dienstag JL, Shiffman ML, Seeff LB, Bonkovsky HL, Morishima C, Wright EC, Snow K, Stoddard A, Digestive Diseases Week, New Orleans, 1/1/2010
• Progression of Advanced Chronic Hepatitis C (CHC): Further Follow-up Results from the HALT-C Trial.
  Dienstag JL, Bonkovsky HL, Kim H-Y, Seeff LB, Di Bisceglie AM, Szabo G, Wright EC, Digestive Diseases Week, New Orleans, 1/1/2010
• Association of host pharmacodynamic effects and virologic response to peginterferon alfa-2A/ribavirin in patients with chronic hepatitis C.
  Chung RT, Di Bisceglie AM, Poordad FF et al, J Hepatol, 1/1/2010
• Improved sustained virologic response (SVR) rates in "difficult-to-cure" patients treated with telaprevir in combination with peginterferon alfa-2A and ribavirin: An a...
  Manns MP, Muir AJ, Adda N, McHutchison JG, Terrault N, Bengtsson L, George S, Di Bisceglie AM, J Hepatol, 1/1/2010
• Early virological response profiles with telaprevir (T) in combination with peginterferon-alfa-2A (P) and ribavirin in genotype 1 HCV treatment-naive and treatment-exp...
  Poordad F, McHutchison JG, Shiffman ML, Berg T, Muir AJ, Manns MP, Di Bisceglie AM et al, J Hepatol, 1/1/2010
• Pharmacogenomic analysis reveals improved virologic response in all IL-28B genotypes in naive genotype 1 chronic HCV patients treated with GI-5005 therapeutic vaccine ...
  McHutchison JG, Thompson AJ, Jacobson IM, Boyer TD, Schiff ER, Everson GT, Vierling JM, Shiffman ML, Brown RS, Di Bisceglie AM et al, J Hepatol, 1/1/2010
• Maintenance peginterferon (pegIFN) therapy to prevent hepatocellular carcinoma (HCC) in patients (pts) with advanced chronic hepatitis C (CHC): extended follow-up resu...
  Anna S. Lok, James E. Everhart, Elizabeth C. Wright, Timothy R. Morgan, Adrian M. Di Bisceglie, Hae-Young Kim, HALT-C Trial Group, Hepatology, 1/1/2010
• Frequency of Elevated Hepatocellular Carcinoma (HCC) Biomarkers (AFP, AFP-L3, and DCP) in Patients (pts) with Chronic Hepatitis C (CHC) and Advanced Fibrosis with and ...
  Richard K. Sterling, Elizabeth C. Wright, Timothy R. Morgan, Leonard B. Seeff, John C. Hoefs, Adrian M Di Bisceglie, Jules L. Dienstag, Anna S. Lok, HALT-C Trial Group, Hepatology, 1/1/2010
• Telaprevir in combination with peginterferon and ribavirin in genotype 1 HCV treatment naive patients: Final results of phase 3 ADVANCE study.
  Jacobson IM, McHutchison JG, Dusheiko GM, Di Bisceglie AM et al, Hepatology, 1/1/2010
• Continued efficacy and safety through 4 years of tenofovir disproxil fumarate (TDF) treatment in HBeAg-negative patients with chronic hepatitis B (Study 102): prelimin...
  Marcellin P, Buti M, Krastev Z, Gurel S, Di Bisceglie AM et al, Hepatology, 1/1/2010
• PROVE# Final Results and 1-year durability of SVR with Telaprevir-Based regimen in hepatitis C genotype-1 infected patients with prior non-response, viral breakthrough...
  McHutchison JG, Manns MP, Muir A, Terrault N, Jacobson IM, Afdhal NH, Heathcote J, Zeuzem S, Reesink HW, Bsharaf M, George S, Adda N, Di Bisceglie AM, Hepatology, 1/1/2009
• The natural history of hepatitis C treatment failures: A meta-analysis.
  Singal A, Volk ML, Jensen DM, Di Bisceglie AM, Schoenfeld P, Hepatology, 1/1/2009
• Rate of curative treatment for early stage hepatocellular carcinoma-Results from the Liver Cancer Research Network.
  Kanwal F, Befeler A, Xu C, Zerinque A, Di Bisceglie AM, Hepatology, 1/1/2009
• Occurrence of hepatitis C-related hepatocellular carcinoma in the absence of cirrhosis: results from the HALT-C Trial.
  Sterling R, Di Bisceglie AM, Curto T, Morgan TR, Seeff LB, Hoefs JC, Goodman ZD, Lok AS, Second Annual Conference of the International Liver Cancer Association, Chicago, 9/5/2008
• Type of response to prior pegylated interferon alfa-2b (12kD)/RBV predicts subsequent response to retreatment with peginterferon alfa-2a (40kD)/RBV.
  Marcellin P, Freilich BL, Andreone P, Di Bisceglie AM et al, Gastroenterology, 1/1/2008
• HCV-RNA status at week 12 of treatment with peginterferon alfa-2a/RBV predicts SVR in patients with prior non-response to pegylated interferon alfa-2b/RBV: Results fro...
  Marcellin P, Freilich BL, Andreone P, Di Bisceglie AM et al, Gastroenterology, 1/1/2008
• Easy-to-assess on treatment parameters correlate with degree of virological response after 12 weeks of treatment.
  Jensen DM, Freilich BL, Andreone P, Di Bisceglie AM et al, Gastroenterology, 1/1/2008
• Easy to assess on-treatment parameters correlate with degree of virological response after 12 weeks of treatment.
  Jensen D, Freilich B, Andreone P, Di Bisceglie AM et al, J Hepatol, 1/1/2008
• HCV-RNA status at week 12 of treatment with peginterferon alfa-2A/RBv predicts SVR in patients with prior non-response to pegylated interferon alfa-2A/RBV: results fro...
  Marcellin P, Freilich B, Andreone P, Di Bisceglie AM et al, J Hepatol, 1/1/2008
• Type of response to prior pegylated interferon alfa-2B (12KD)/RBV predicts subsequent response to retreatment with peginterferon alfa-2A(40KD)/RBV.
  Marcellin P, Freilich B, Andreone P, Di Bisceglie AM et al, J Hepatol, 1/1/2008
• Association of pretreatment and on-treatment factors with null response in patients with chronic hepatitis C treated with peginterferon alfa-2° and ribavirin.
  Di Bisceglie AM, Hassanein TI, Jeffers LJ et al, J Hepatol, 1/1/2008
• Incidence and risk factors associated with hepatocellular carcinoma (HCC) in patients with advanced liver disease due to hepatitis C: results of the HALT-C Trial.
  Lok AS, Seeff LB, Morgan TR, Di Bisceglie AM et al, J Hepatol, 1/1/2008
• HCV in liver cancer patients has characteristic mutations in the core gene.
  Fishman S, Factor S, Balestrieri C, Desai SM, Di Bisceglie AM, Benson D, Branch AD, Hepatology, 1/1/2008
• Novel fucosylated biomarkers for the early detection of hepatocellular carcinoma.
  Mehta A, Marrero J, Junaidi O, Di Bisceglie AM, Block TM, Hepatology, 1/1/2008
• A phase 2B study of telapravir with peginterferon-alfa-2A and ribavirin in hepatitis C genotype 1 null and partial responders and relapsers following a prior course of...
  McHutchison JG, Shiffman ML, Terrault N, Manns MP, Di Bisceglie AM et al, Hepatology, 1/1/2008
• Antigen-specific lymphocyte proliferation decreases over time in advanced chronic hepatitis C and its loss is associated with the presence of cirrhosis.
  Morishima C, Di Bisceglie AM, Koziel MJ et al, Hepatology, 1/1/2008
• A 72 week treatment duration with peginterferon alfa-2A (40kD) (PEGASYS) plus ribavirin (Copegus) has a favorable risk:benefit ratio in non-responders to pegylated int...
  Marcellin P, Craxi A, Brandao-Mello CE, Di Bisceglie AM et al, Hepatology, 1/1/2008
• The prevalence of viral hepatitis with cirrhosis and hepartocellular carcinoma (HCC) in Egypt.
  Ryu SH, Kumari R, Osmack P, Xu Y, Fan X, Omar A, Di Bisceglie AM, Gut and Liver, 1/1/2007
• Therapy of hepatitis C.
  Di Bisceglie AM, Gut and Liver, 1/1/2007
• Baseline parameters predict both early virologic response and longer term outcomes for telbivudine treated patients with chronic hepatitis B (the GLOBE study).
  Zeuzem S, Gane EJ, Liaw YF, Di Bisceglie AM et al, Hepatology, 1/1/2007
• On-treatment virologic suppression at week 24 decreases the risk of histologic progression at 1 year: Data from the GLOBE trial.
  Benhamou Y, Di Bisceglie AM, Goodman ZD et al., Hepatology, 1/1/2007
• Retreatment of treatment experienced HCV patients with pegylated interferon alfa-2A and thymosin alpha-1: Pooled analysis of two randomized controlled trials.
  Sherman KE, Gordon SC, Iftikhar R, Rodriguez-Torres M, Rustgi VK, Di Bisceglie AM et al, Hepatology, 1/1/2007
• Prolonged antiviral therapy with peginterferon to prevent complications of advanced liver disease associated with hepatitis C: results of the hepatitis C antiviral lon...
  Di Bisceglie AM, Shiffmann ML, Everson GT et al, Hepatology, 1/1/2007
• Pegylated interferon alfa-2A (40kD) plus ribavirin (RBV) in prior non-responders to pegylated interferon alfa-2B (12kD)/RBV: Final efficacy and safety outcomes of the ...
  Jensen DM, Freilich B, Andreone P, Di Bisceglie M et al, Hepatology, 1/1/2007
• Hepatocellular carcinoma: Why early diagnosis is needed.
  Di Bisceglie AM, Global Antiviral Journal, 1/1/2007
• Peginterferon alfa-2a (40KD) plus ribavirin (RBV) in pegylated interferon alfa-2b (12kD)/ribavirin nonresponders: Week 12 efficacy and safety outcomes of the REPEAT St...
  Jensen D, Di Bisceglie AM, Gitlin N, Freilich B, Reddy KR, FeinmanV, Arora S, Marcellin P, Gastroenterology, 1/1/2006
• Peginterferon alfa-2b (40KD) (PEGASYS) plus ribavirin (RBV) (Copegus) in pegylated interferon alfa-2b (12kD)/ribavirin nonresponders with cirrhosis/advanced fibrosis: ...
  Gitlin N, Di Bisceglie AM, Marcellin P, Bonkovsky H, Rai R, Rizzetto M, Teuber G, Jensen D, Gastroenterology, 1/1/2006
• Cost effectiveness of antivirals in HBeAg-positive chronic hepatitis B: Impact of seroconversion and viral suppression.
  Veenstra DL, Iloeje UH, Tafesse E, Sullivan SD, Cross A, Di Bisceglie AM, Gish RG, Gastroenterology, 1/1/2006
• Estimating the burden of liver disease in the United States using administrative claims data.
  Di Bisceglie AM, Gavard JA, Stirneman P, Xiao H. Burroughs TE, Schnitzler MA, Takemoto SK, Gastroenterology, 1/1/2006
• Smoking increases the risk of hepatocellular carcinoma in cirrhosis.
  Abdelaziz A, Dakjil N, Elbaz T, Shebab H, Zekri A, Di Bisceglie AM, Liver International, 1/1/2006
• Two-year results from the GLOBE trial in patients with hepatitis B: Greater clinical and antiviral efficacy for telbivudine (LDT) vs. lamivudine.
  Lai C-L, Gane E, Hsu C-W, Thongsawat S, Wang Y, Chen Y, Heathcore EJ, Rasenack J, Bzowej, Nauomov N, Zeuzem S, Di Bisceglie AM et al, Hepatology, 1/1/2006
• Mutations in genotype 1A HCV of liver cancer patients occur in the =1 reading frame, not in the core protein.
  Fishman S, Balestrieri C, Fan X, Xing J, Di Bisceglie AM, Branch AD, Hepatology, 1/1/2006
• Clinical, biochemical, virologic and histologic outcomes of chronic hepatitis C following sustained virologic response (SVR) to HCV therapy: A prospective 5 year cohor...
  Di Bisceglie AM, George SL, Mihindulasuriya L, Hoffman J, Bacon BR, Hepatology, 1/1/2006
• Quality of care in chronic hepatitis C virus (HCV) infection.
  Kanwal F, Spiegel BM, Goetz M, Gralnek IM, Dominitz JA, Di Bisceglie AM, Asch S, Hepatology, 1/1/2006
• Telbivudine GLOBE trial: maximal early HBV suppression is predictive of optimal two-year efficacy in nucleoside-treated hepatitis B patients.
  Di Bisceglie AM, Lai C-L, Gane E et al, Hepatology, 1/1/2006
• Serum fibrosis markers predict future clinical decompensation in primary biliary cirrhosis better than liver biopsy, bilirubin or Mayo risk score.
  Mayo MJ, Parks J, Huet B, Combes B, Mills SA, Markin R, Rubin R, Wheeler D, Contos M, West B, Saldana S, Getachew Y, Butsch R, Luketic VA, Peters M, Di Bisceglie AM, e..., Hepatology, 1/1/2006
• The natural history of chronic hepatitis B infection: a new computer simulation model to incorporate events subsequent to HBeAg seroconversion.
  Kim, WR, Veenstra D, Oloeje UH, Tafesse E, Atillasoy E, Di Bisceglie AM, Kowdley K, Gastroenterology, 1/1/2005
• Are serial liver biopsies useful in assessing disease progression in individuals with primary biliary cirrhosis?
  Saldana S, Frawley W, Combes B, Mills S, Markin R, Rubin R, Wheeler D, Contos M, West B, Flye N, Butsch R, Emerson S, Carithers R, Luketic V, Benner K, Peters M, Di Bi..., Gastroenterology, 1/1/2005
• Management of chronic hepatitis B-an analysis of physician practices.
  Di Bisceglie A, Keeffe E, Atillasoy E, Varshneya R, Bergstein G, Gastroenterology, 1/1/2005
• A phase I safety and immunogenicity trial of a novel E1E2/MF59c1 hepatitis C vaccine candidate in healthy HCV-negative adults.
  Frey SE, Di Bisceglie AM, Gorse GJ, Ray R, Houghton M, Schultze V, Abrignani S, Coates S, Belshe R, Hepatology, 1/1/2005
• Iron and HFE gene mutations in advanced chronic hepatitis C (CHC): Results from the lead-in phase of the HALT-C Trial.
  Bonkovsky HL, Di Bisceglie AM, et al, Hepatology, 1/1/2005
• Interim safety analysis of patients enrolled in the randomized, international retreatment with Pegasys in patients not responding to prior peginterferon alfa-2B/ribavi...
  Marcellin P, Freilich B, Andreone P, Brandoao-Mello CE, Di Bisceglie AM, et al, Hepatology, 1/1/2005
• Genetic and biochemical evidence for action of ribavirin through the HCV RNA polymerase in vivo.
  Cannon NA, Metzger LM, Donlin MJ, Lyra A, Yao E, Di Bisceglie AM, Tavis JE, 11th International Symposium on hepatitis C and related viruses, Heidelberg, Germany, 10/1/2004
• Full length sequencing of HCV identifies novel regions of the viral genome associated with response to antiviral therapy.
  Di Bisceglie AM, Tan D, Fan X, Tavis JE, Kuiken C, 11th International Symposium on hepatitis C and related viruses, Heidelberg, Germany, 10/1/2004
• Development of a replicon-based shuttle vector system for phenotypic characterization of HCV patient NS5B genes towards polymerase inhibitors.
  Middleton T, Lim HB, Pilot-Matias T, Tripathi R, Roth A, Koev G, Ng T, Liangjun L, Pithawalla R, Chen-C-M, Kati W, Mo H, Di Bisceglie A, Molla A, 11th International Symposium on hepatitis C and related viruses, Heidelberg, Germany, 10/1/2004
• Interferon-gamma stimulated chemokines predict treatment outcome in patients with chronic HCV infection.
  Butera D, Marukian S, Jacobson IM, Di Bisceglie AM, Chambers TJ, Rice CM, Dustin LB, 11th International Symposium on hepatitis C and related viruses, Heidelberg, Germany, 10/1/2004
• Full length genome analysis of hepatitis C virus in patients with differential responses after combined therapy of pegylated interferon-alpha and ribavirin.
  Tan D, Yao E, Fan X, Chambers T, Tavis J, Di Bisceglie AM, Gastroenterology, 1/1/2004
• Antioxidant treatment does not substantially ameliorate the fall in hemoglobin in HCV patients treated with pegylated interferon alfa-2b and ribavirin.
  Bacon BR, Freilich BL, Siegner JM, O'Neill R, Kissinger J, Hoffmann JA, Britton RS, Di Bisceglie AM, Brass CA, Gastroenterology, 1/1/2004
• The epidemiology and survival of patients with hepatocellular carcinoma in the United States-A preliminary report from the Liver Cancer Network.
  Befeler AS, Marrero JA, Chari RS, Roberts L, Afdhal N, Van Thiel D, Di Bisceglie AM, Hepatology, 1/1/2004
• Liver biopsy evaluation in work up of hepatic lesions suspicious for hepatocellular carcinoma.
  Bialecki A, Ezenekwe A, Brunt EM, Collins BT, Ponder TB, Bieneman BK, Di Bisceglie AM, Hepatology, 1/1/2004
• Prevalence of insulin resistance (IR) and impact on treatment in chronic hepatitis C (CHC).
  Lok AS, Everhart JE, Chung RT, Padmanbhan L, Shiffman ML, Everson GT, Lindsay KL, Bonkovsky HL, Di Bisceglie AM, Le WM, Morgan TR, Ghany MG, Morishima C, Hepatology, 1/1/2004
• Pharmacokinetics and pharmacodynamics of pegylated interferon alfa-2A or alfa-2B with ribavirin in treatment naive patients with genotype 1 chronic hepatitis C.
  Di Bisceglie AM, Rustgi VK, Thuluvath P, Davis M, Ghalib R, Lyons MF, Ondovik MS, Lopez-Talavera JC, Hamzeh F, Hepatology, 1/1/2004
• HCV quasispecies dynamics during combination therapy of peginterferon alfa 2A and ribavirin.
  Fan X, Droll DA, Xu Y, Chambers TJ, Di Bisceglie AM, Gastroenterology, 1/1/2003
• Gastrointestinal surgery in patients with cirrhosis.
  Hoffman MG, Longo WE, Bahadursingh A, Di Bisceglie AM, Gastroenterology; Digestive Diseases Week, 1/1/2003
• The presence of severe steatosis or steatohepatitis impairs response to antiviral therapy in patients with chronic hepatitis C.
  Harrison SA, Brunt EM, Oliver DA, Neuschwander-Tetri BA, Di Bisceglie AM, Bacon BR, Hepatology, 1/1/2003
• Monitoring HCV core antigen during antiviral therapy.
  Di Bisceglie AM, Strinko J, Osmack P, Hepatology, 1/1/2003
• Early pharmacokinetics, pharmacodynamics and hepatitis C viral kinetics on treatment with pegylated interferon (IFN) alfa-2a with or without ribavirin: characterizatio...
  Di Bisceglie AM, Osmack P, Hoffman J, Strinko J, Hepatology, 1/1/2003
• Serum alpha-fetoprotein (AFP) levels in patients with advanced hepatitis C-associated liver disease without hepatocellular carcinoma: results from the HALT-C trial.
  Di Bisceglie AM, Dienstag J, Bonkovsky H, Sterling R, Chung R, Everhart J, Wright E, for the HALT-C investigators, Hepatology, 1/1/2003
• The presence and spectrum of varices in the absence of cirrhosis in patients with chronic hepatitis C.
  Sanyal AJ, Fontana R, Everhart J, Di Bisceglie AM, Wright E, Hepatology, 1/1/2003
• HCV-specific immune responses at baseline do not predict virologic response to antiviral therapy in advanced hepatitis C.
  Morishima C, Ray R, Polyak SJ, Sullivan DG, Chang M, Di Bisceglie AM, Lee WM, Bonkovsky HL, Gretch DR, Wright EC, Rothman AL, Koziel MJ, Lindsay KL, Hepatology, 1/1/2003
• Diabetic hepatosclerosis: perisinusoidal hepatic fibrosis without steatohepatitis among diabetics.
  Harrison SA, Brunt EM, Goodman ZD, Di Bisceglie AM, Hepatology, 1/1/2003
• Portal hypertensive gastropathy is prevalent amongst chronic hepatitis C non-responders with bridging fibrosis and early cirrhosis: results from the HALT-C trial.
  Fontana RJ, Sanyal AJ, Wright E, Di Bisceglie AM, Hepatology, 1/1/2003
• Host immune responses do not correlate with histologic injury: baseline analysis of the HALT-C trial in advanced hepatitis C disease.
  Rothman AL, Morishima C, Ray R, Bonkovsky HL, Di Bisceglie AM, Lee WM, Lindsay, KL, Gretch DR, Polyak SJ, Wright EC, Koziel MJ, Hepatology, 1/1/2003
• GP73, a resident Golgi membrane protein, appears in sera or patients with viral liver disease and hepatocellular cancer.
  Romano PR, Nikolaeva OV, Steel L, Fimmel CJ, Marrero J, Evans AA, Communale MA, Lok A, London WT, Di Bisceglie AM, Block TM, Hepatology, 1/1/2003
• Lifetime alcohol and drug abuse disorders are significantly more common in HALT-C patients compared to population controls while mood disorders are less common.
  Fontana RJ, Kronfol Z, Wright E, Lindsay K, Seeff L, Shiffman M, Di Bisceglie A, Bonkovsky H, Everson G, Lok ASF, Lee WM, Dienstag J, Morgan T, Morshima C, Ghany M for..., Gastroenterology; Digestive Diseases Week, 1/1/2002
• HCV RNA and immunological responses to thymalfasin in combination with peginterferon alfa-2a in HCV non-responders: A 12-week kinetic study.
  Iftikar R, Di Bisceglie A, Pockros PJ, Rustgi VK, Schulman M, Martins EB, Hepatology, 1/1/2002
• Clonal nature of hepatitis C virus: Full length sequencing shows lack of recombination of HCV isolates from heterologous HCV positive recipient/donor pairs in liver tr...
  Fan X, Xu Y, Lang D, Detre KM, Belle SH, Wei YL, Wiesner RH, Charlton MR, Schafer D, Bass N, Roberts J, Korber BTM, Everhart JE, Di Bisceglie AM, Hepatology, 1/1/2002
• Derivation, origin-dating and assembly of ancestral hepatitis C virus (HCV) envelope sequences.
  Fan X, Di Bisceglie AM, Hepatology, 1/1/2002
• Retreatment of HCV non-responders with peginterferon and ribavirin: Results from the lead-in phase of the hepatitis C antiviral long-term treatment against cirrhosis (...
  Shiffman M and the HALT-C trial investigators, Hepatology, 1/1/2002
• Chemoprevention of hepatocellular carcinoma by Tamoxifen.
  Di Bisceglie AM, Osmack P, Brunt EM, Hepatology, 1/1/2002
• Peripheral blood B cell expansion in HCV infection is not associated with activation or differentiation.
  Dustin LB, Ni J, Hembrador EG, Chambers TJ, Di Bisceglie AM, Dorante G, Talal AH, Jacobson IM, Rice CM, 9th International Meeting on HCV and Related Viruses, Center for the Study of Hepatitis C, Rockefeller University, 1/1/2002
• Join now to see all

Other

• Audio CD: "Management of chronic hepatitis C in the era of direct-acting antiviral agents." 
  Di Bisceglie AM, Audio Digest Gastroenterology, Vol 26 (Issue 17)
  9/7/2012
• The Clinician's Companion VII: Expert Perspectives on Contemporary Clinical Issues in Hepatitis C. 
  Di Bisceglie AM, "Relationship between chronic HCV infection and hepatocellular carcinoma.", Projects in Knowledge, p
  1/1/2005
• "Digestive Diseases Week 2004 CME Program" 
  Di Bisceglie AM
  http://www.medscape.com/viewprogram/3103
  1/1/2004
• Natural history of hepatitis C. 
  Di Bisceglie AM, Clinical Care Options for Hepatitis, Annual Update, IMedOptions, pp. 3-12
  1/1/2003
• Nonalcoholic liver disease: An emerging view of its significance and management. 
  Di Bisceglie AM, Medscape Gastroenterology/Digestive Diseases Week Conference Coverage
  http://www.medscape.com/viewprogram/1846
  1/1/2002
• "Raising hepatitis C awareness." 
  Di Bisceglie AM, HealthTalk Interactive's Hepatitis C Education Network
  http://www.healthtalk.com
  1/30/2001
• Liver diseases. (Instructional pamphlet) 
  Di Bisceglie AM, SLUCare/Tenet
  1/1/2001
• Hepatocellular carcinoma. In, The Clinician's Companion V: Expert perspectives on contemporary issues in hepatitis C. Part 2: Insights into the pathogenesis, treatment... 
  Di Bisceglie AM, Rakela J, Projects in Knowledge, pp. 11-15
  1/1/2001
• The Clinician's Companion IV: Expert Perspectives on Contemporary Clinical Issues in Hepatitis C. Part 3: Insights into pathogenesis, treatment effects, and management... 
  Di Bisceglie AM, Kwo PY, Rustgi VK, Projects in Knowledge, pp. 9-12
  1/1/2001
• "How do you manage the patient with hepatitis B and hepatitis C dual infection?" 
  Di Bisceglie AM, Medscape "Ask the Experts-Hepatitis C"
  12/14/2000
• New developments in hepatocellular carcinoma. 
  Di Bisceglie AM, American Association for the Study of Liver Diseases 51st Annual Meeting and Postgraduate Course
  http://www.medscape.com/Medscape/CNO/2000/AASLD/Story
  1/1/2000
• "Viral Hepatitis." 
  Di Bisceglie AM, Digestive Diseases Self-Education Program II (DDSEP) for the American Gastroenterological Associatio
  1/1/2000
• Rising Incidence of Hepatocellular Carcinoma. 
  Di Bisceglie AM, Medscape AASLD-Advances in Hepatocellular Carcinoma
  http://gastroenterology.medscape.com/Medscape/CNO/1999/AASLD/public/index-AASLD.html
  12/1/1999
• The Clinician's Companion III: Expert perspectives on contemporary clinical issues in hepatitis C. (CD-ROM) 
  Di Bisceglie AM, Education Initiatives in Gastroenterology Meeting
  6/18/1999
• Emerging therapies for chronic hepatitis C. 
  Di Bisceglie AM, Audiotape: Beyond Monotherapy: Next Generation Therapies for Chronic Hepatitis C; Education Initiati
  New Orleans - 5/17/1998
• Hepatocellular carcinoma. 
  Di Bisceglie AM, The clinician's companion: expert perspectives on contemporary clinical issues in hepatitis C, pages
  1/1/1997
• (Tape) Hepatitis C recommendations. 
  Di Bisceglie AM, Audio Journal of Haematology
  1/1/1994
• Combined infection with hepatitis B and hepatitis C. 
  Di Bisceglie AM, Hepatitis forum, Abbott Labs, page 12
  1/1/1994
• Extra-hepatic manifestations of chronic viral hepatitis. 
  Shakil OA, Di Bisceglie AM, 'L' Internista'
  1/1/1994
• (Tape) Treatment of chronic viral hepatitis. 
  Di Bisceglie AM, Practical Reviews in Gastroenterology
  1/1/1989
• A randomized controlled trial of a 4 month course of recombinant human alpha interferon in patients with chronic type B hepatitis. 
  Di Bisceglie AM, Hoofnagle JH, Peters M, Mullen KD, Jones DB, Rustgi VK, Avigan MI, Park Y, Waggoner JG, Jones EA. In, Schellekens H, Cantell K, Proceedings of the 1986 ISIR/TNO Meeting; Martinus Nijhoff
  Dordrecht, The Netherlands - 1/1/1987
• Join now to see all